Physician profile
Kenneth K Ellis
NPI 1114902228
$2,959.81
in general payments reported to CMS, 2019-2025
29 companies · $378 in 2025
The $378 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $468 · 2021: $379 · 2022: $529 · 2023: $389 · 2024: $329 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082 · Education: $14.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.94 |
| Education | $14.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,475.73 | 2019-2025 | |
| Celgene Corporation | $219.58 | 2021-2024 | Zeposia |
| Pfizer INC. | $185.68 | 2019-2025 | |
| Gilead Sciences, INC. | $177.64 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.58 | 2019-2022 | |
| Allergan, INC. | $89.98 | 2019-2020 | |
| Romark Laboratories, Lc | $83.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.66 | 2020-2022 | |
| Medtronic, INC. | $79.24 | 2024 | Gi Genius |
| Daiichi Sankyo INC. | $42.54 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $41.18 | 2021 | |
| Qol Medical, LLC | $39.74 | 2022-2025 | Sucraid |
| Braintree Laboratories, INC. | $28.74 | 2021 | |
| Janssen Biotech, INC. | $26.32 | 2021-2023 | Simponi, Remicade, Simponi Aria |
| Genzyme Corporation | $24.64 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $24.64 | 2022 | |
| Merck Sharp & Dohme LLC | $24.41 | 2023 | Zerbaxa, Dificid, Recarbrio |
| Mauna Kea Technologies, INC. | $21.98 | 2025 | |
| Ardelyx, INC. | $21.21 | 2025 | Ibsrela |
| Blueprint Medicines Corporation | $19.80 | 2022 | |
| Endo Pharmaceuticals INC. | $16.39 | 2020 | |
| Vivus LLC | $15.71 | 2022 | |
| Celltrion USA INC. | $14.42 | 2024 | Zymfentra |
| Nestle Healthcare Nutrition INC. | $14.06 | 2023 | |
| Boston Scientific Corporation | $13.66 | 2021 | |
| Ferring Pharmaceuticals INC. | $12.47 | 2022 | |
| Redhill Biopharma INC. | $11.42 | 2020 | |
| Intercept Pharmaceuticals, INC. | $11.10 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,796.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.